Biotie Therapies Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biotie therapies inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biotie Therapies Inc Today - Breaking & Trending Today

Cocaine Use Disorder Market Size in the 7MM was approximately USD 50 Million in 2023, estimates DelveInsight |

Cocaine Use Disorder Market Size in the 7MM was approximately USD 50 Million in 2023, estimates DelveInsight |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

United States , University Of Massachusetts , Embera Neurotherapeutics , Eli Lilly , Yashveer Bhardhwaj , Embera Neurotherapeutics Inc , Novartis Pharmaceuticals , Emmes Company , Tempero Bio Inc , Cocaine Use Disorder Market Research , Indivior Inc , Market Research , Somerset Pharmaceuticals , Healthcare Services , Biotie Therapies Inc , Alkermes Inc , Catalyst Pharmaceuticals Inc , Cocaine Use Disorder Embera Neurotherapeutics Inc , Umass Medical School , University Of North Carolina At Chapel Hill , Cocaine Use Disorder Companies , Cocaine Use Disorder Market , Use Disorder , Cocaine Use Disorder , Cocaine Use Disorder Pipeline Therapies , Tempero Bio ,

Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals

29.08.2022 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the . Seite 1 ....

Asieris Pharmaceuticals , Biotie Therapies Inc , Acorda Therapeutics Inc , Acorda Therapeutics , Biotie Therapies ,

Athersys Announces CEO Transition

Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces CEO Transition
CLEVELAND, Ohio (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer. Dr. Ismail Kola, Lead Director of the Athersys Board, has been appointed Chairman of the Board.
The Company’s Board is commencing a comprehensive search process to identify a permanent CEO. The Board intends to identify and select a CEO who can guide Athersys in the commercial stage. ....

University Of Chicago , United States , United Kingdom , University Of Cape Town , Western Cape , South Africa , Washington University , South Australia , Van Bokkelen , Gil Van Bokkelen , Williambj Lehmann , Goodrich Rosati , Ivor Macleod , John Harrington , Ondek Pty Ltd , Corporate Communications Investor Relations , Russo Partners , University Of South Africa , Human Disease At Monash Medical School , Cambridge University , Early Clinical Research Experimental Medicine At Schering , Plough Research Institute , Monash University Medical School , First Chicago Corporation , Rhodes University , Nuffield School Of Medicine ,